CHC Groupe santé reposted this
PFO closure still comes with significant challenges… Excited to share the publication of our latest research article on atrial fibrillation post PFO closure, “a multicenter analysis of implantable monitoring device-based diagnosis of supraventricular arrhythmia post patent foramen ovale closure: the OCCL-ILR study" in Frontiers-Medicine, Cardiovascular Medicine. https://lnkd.in/efFcQbuc ✔ First multicenter analysis focusing on supraventricular arrhythmia (AF, atrial flutter or any supraventricular tachycardia) post PFO closure with the Occlutech PFO device ✔ Per-protocol implantable device monitoring for at least 3 months pre-closure and 1 month post-closure, with a core lab second read of all EGM’s. ✔ Diagnosis of new-onset supraventricular arrhythmia (97% AF) in 31% of patients, in line with other recent single-center reports using other (or combination of) PFO closure devices. ✔ 94% of new-onset occurred in the first 45days after PFO closure, but 33% of patients with supraventricular arrhythmia post PFO closure presented AF episodes beyond 60days post closure. Thank you to all collaborating centers: AZ Sint-Lucas Gent, Kurt Hermans, Frauke Gorré AZORG Aalst, Julie Colas-Florial, Liesbeth Rosseel AZ Delta Roeselaere, Philippe Muyldermans, Maarten Pauwelyn CHC Groupe santé Clinique Montlégia Luik,Pieter-Jan Palmers, François Delvoye UZ Brussel, Vrije Universiteit Brussel, Daniele Plein, Jonas Podevyn, Bram Roosens, Steven Droogmans, Jean-françois Argacha, Sylvie De Raedt, Gian Battista Chierchia Special word of thanks to Alvise Del Monte, Xavier Galloo, Andreea Motoc, Evelyne Wirix, Philippe Unger and Bernard Cosyns for their invaluable support! #proud to be Brussels #structural heart interventions #Centrum voor Hart- en Vaatziekten UZ Brussel